540 related articles for article (PubMed ID: 24300483)
1. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
Lavery HJ; Stensland KD; Niegisch G; Albers P; Droller MJ
J Urol; 2014 Apr; 191(4):898-906. PubMed ID: 24300483
[TBL] [Abstract][Full Text] [Related]
2. A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer.
Mitra AP; Skinner EC; Miranda G; Daneshmand S
BJU Int; 2013 Feb; 111(2):240-8. PubMed ID: 22928881
[TBL] [Abstract][Full Text] [Related]
3. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy in patients with invasive bladder cancer.
Vaughn DJ; Malkowicz SB
Urol Clin North Am; 2005 May; 32(2):231-7. PubMed ID: 15862620
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
Pruthi RS; Nielsen M; Heathcote S; Wallen EM; Rathmell WK; Godley P; Whang Y; Fielding J; Schultz H; Grigson G; Smith A; Kim W
BJU Int; 2010 Aug; 106(3):349-54. PubMed ID: 20089114
[TBL] [Abstract][Full Text] [Related]
6. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
Tilki D; Svatek RS; Novara G; Seitz M; Godoy G; Karakiewicz PI; Kassouf W; Fradet Y; Fritsche HM; Sonpavde G; Izawa JI; Ficarra V; Lerner SP; Schoenberg M; Stief CG; Dinney CP; Skinner E; Lotan Y; Sagalowsky AI; Reich O; Shariat SF
J Urol; 2010 Sep; 184(3):888-94. PubMed ID: 20643448
[TBL] [Abstract][Full Text] [Related]
7. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.
Meeks JJ; Taylor JM; Matsushita K; Herr HW; Donat SM; Bochner BH; Dalbagni G
BJU Int; 2013 Jun; 111(8):E325-30. PubMed ID: 23384236
[TBL] [Abstract][Full Text] [Related]
8. What is the significance of pT0 at cystectomy?
Hotston M; Patel S; Sohail M; Persad RA
Surg Oncol; 2006 Aug; 15(2):65-9. PubMed ID: 16971115
[TBL] [Abstract][Full Text] [Related]
9. Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study.
Rouprêt M; Drouin SJ; Larré S; Neuzillet Y; Botto H; Hitier M; Rigaud J; Crew J; Xylinas E; Salomon L; Cornu JN; Iborra F; Champetier D; Rozet F; Flamand V; Bastide C; Cormier L; Durand X; Lunardi P; Rischmann P; Nouhaud FX; Ferlicot S; Patard JJ; Floch AP; Irani J; Peyronnet B; Bensalah K; Poissonnier L; Grès P; Droupy S; Casenave J; Wallerand H; Soulié M; Pfister C;
Ann Surg Oncol; 2011 Dec; 18(13):3833-8. PubMed ID: 21647762
[TBL] [Abstract][Full Text] [Related]
10. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
11. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1?
Zargar H; Zargar-Shoshtari K; Lotan Y; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black P;
J Urol; 2016 Apr; 195(4 Pt 1):886-93. PubMed ID: 26521718
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
[TBL] [Abstract][Full Text] [Related]
14. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
[TBL] [Abstract][Full Text] [Related]
15. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
16. Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder.
May M; Bastian PJ; Burger M; Bolenz C; Trojan L; Herrmann E; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Otto W; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Wieland WF; Fritsche HM
BJU Int; 2011 Oct; 108(8 Pt 2):E278-83. PubMed ID: 21699644
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
19. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
20. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
Izawa JI; Chin JL; Winquist E
Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
